MaleHairAdvice
Pharmacology & Safety

Comparing 5-AR Inhibitors Head to Head: The Efficacy Hierarchy

5 min read July 2026 Peer-reviewed sources

Affiliate disclosure: This page contains sponsored links. We earn commissions at no extra cost to you. Clinical content is editorially independent.

Among 5-AR inhibitors, dutasteride demonstrates greater hair density benefit than finasteride in head-to-head comparisons. The biological reason is the difference in DHT suppression depth and isoform coverage.

The 5-alpha-reductase inhibitor class contains two clinically used agents for AGA — finasteride and dutasteride — with different pharmacological profiles that produce different clinical outcomes. The hierarchy is pharmacologically predictable and clinically confirmed.

Mechanism comparison

Property Finasteride 1mg Dutasteride 0.5mg
5-AR isoforms inhibited Type 2 (selective) Type 1 and Type 2 (dual)
Serum DHT suppression ~65–70% ~90–95%
Elimination half-life ~6 hours ~5 weeks
FDA approval for AGA Yes (1mg, 1997) No (US off-label); Yes (Japan, South Korea)

Head-to-head clinical evidence

Multiple studies compare finasteride and dutasteride directly in AGA. The consistent finding: dutasteride produces greater increases in hair count and density measurements than finasteride at comparable treatment durations. A 2023 systematic review and meta-analysis confirmed dutasteride's superiority across available randomised trials.

Choosing between them

Finasteride is the rational first-line choice for most men: FDA-approved for AGA, well-characterised side effect profile over decades of use, short half-life enabling rapid discontinuation if needed, and well-established efficacy. Dutasteride is appropriate when finasteride has been inadequate (partial response or continued AGA progression despite 12+ months of consistent finasteride), when a more aggressive DHT suppression is clinically indicated, or when the patient is informed of and accepts the different pharmacokinetic profile and off-label status.

Clinical Q&A

Is dutasteride better than finasteride for hair loss?

Based on available head-to-head comparisons and meta-analyses, dutasteride produces greater hair density improvement than finasteride in AGA. The advantage is consistent across studies and is pharmacologically explained by deeper DHT suppression (90–95% vs 65–70%).

Are there 5-AR inhibitors stronger than dutasteride?

Dutasteride is the most potent clinically used 5-AR inhibitor — inhibiting all three isoforms (though primarily 1 and 2) more completely than finasteride inhibits type 2 alone. No approved drug provides meaningfully greater 5-AR inhibition. Research compounds with different mechanisms (AR antagonists like clascoterone) target the androgen pathway at a different step.

What about topical finasteride — how does it compare?

Topical finasteride (available in some compounded formulations) delivers drug locally to the scalp with reduced systemic absorption. Limited but growing evidence suggests comparable hair density benefit to oral at appropriate concentrations, with potentially fewer systemic side effects. Head-to-head trials with oral finasteride are limited; this is an evolving area.

References & further reading

  1. Shapiro J, et al. Comparison of finasteride and dutasteride for the treatment of androgenetic alopecia: a systematic review and meta-analysis. Dermatology and Therapy, 2023.

Get a clinical evaluation

Care Bare Rx

Online consultation with licensed prescribers for hair loss evaluation. Compounded finasteride, minoxidil, and combination formulas prescribed and shipped after a clinical intake review.

Start Your Care Bare Rx Intake

Sesame Care

Direct-booking platform for licensed physician consultations. FDA-approved brand-name and generic hair loss prescriptions at transparent prices, no insurance or membership required.

Browse Sesame Care Providers

Strut Health

Telehealth platform offering prescription hair loss formulations after licensed-provider review of an online intake. Topical and oral options available.

FDA Warning Letter #721448

Strut Health received FDA Warning Letter #721448 (February 2026) regarding misbranding of compounded medications. We disclose this on every Strut appearance and exclude Strut from featured rankings. Weigh this when comparing options.

See Strut Health Options

RxSpan MD

Online medical consultations with licensed prescribers across hair loss and other treatment categories. Direct-to-door fulfilment.

Explore RxSpan MD

Compounded medications: These preparations are made by a pharmacy for an individual patient and are not FDA-approved for safety, effectiveness, or manufacturing quality. Discuss trade-offs with a licensed prescriber.

Affiliate Disclosure: This site earns commissions on referrals at no extra cost to you. Clinical content is independent.

Medical disclaimer: This article is educational and does not constitute clinical advice, diagnosis, or treatment recommendations. Consult a licensed physician or dermatologist before starting, stopping, or changing any medication or treatment for hair loss.